Biomarin Pharmaceutical (BMRN) EBIT Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted EBIT Margin of 16.92% for Q1 2026, up 431.71% on a QoQ basis from 5.1% in Q4 2025, and down 1313.0% year-over-year from 1.39% in Q1 2025.
Biomarin Pharmaceutical (BMRN) EBIT Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's EBIT Margin history runs 18 years deep, the most recent figure standing at 16.92% for Q1 2026.
- Quarterly EBIT Margin fell 1313.0% year-over-year to 16.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.72% (down 1128.0% YoY) and the FY2025 annual result came in at 12.71%, down 425.0% from the prior year.
- EBIT Margin was 16.92% for Q1 2026 at Biomarin Pharmaceutical, up from 5.1% in the prior quarter.
- Across five years, EBIT Margin topped out at 33.55% in Q2 2025 and bottomed at 6.02% in Q3 2025.
- A 5-year average of 11.68% and a median of 11.01% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 2128 bps — and 2025, when it plunged 2670 bps.
- Biomarin Pharmaceutical's EBIT Margin stood at 2.43% in 2022, then jumped by 273 bps to 4.22% in 2023, then soared by 412 bps to 21.6% in 2024, then slumped by 124 bps to 5.1% in 2025, then soared by 432 bps to 16.92% in 2026.
- Business Quant data shows BMRN's EBIT Margin at 16.92% in Q1 2026, 5.1% in Q4 2025, and 6.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 16.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.92% |
| Dec 31, 2025 | -5.10% |
| Sep 30, 2025 | -6.02% |
| Jun 30, 2025 | 33.55% |
| Mar 31, 2025 | 30.05% |
| Dec 31, 2024 | 21.60% |
| Sep 30, 2024 | 15.27% |
| Jun 30, 2024 | 16.92% |
| Mar 31, 2024 | 13.63% |
| Dec 31, 2023 | 4.22% |
| Sep 30, 2023 | 5.25% |
| Jun 30, 2023 | 11.01% |
| Mar 31, 2023 | 10.46% |
| Dec 31, 2022 | -2.43% |
| Sep 30, 2022 | -0.48% |
| Jun 30, 2022 | 7.33% |
| Mar 31, 2022 | 26.44% |
| Dec 31, 2021 | -14.65% |
| Sep 30, 2021 | -13.02% |
| Jun 30, 2021 | 2.33% |